LEXINGTON, Mass., May 20, 2010 (BUSINESS WIRE) –AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that
management will participate in the 2010 Citi Investment Research Global
Healthcare Conference on May 27 at 11:30 a.m. ET. The format of the
conference will be a brief presentation and roundtable discussion
between management and a Citi investment research analyst followed by a
question and answer period from investors in the audience. The
conference is being held May 26-27, 2010 in New York City.
A live webcast will be accessible through the Investors section of the
company’s website at www.amagpharma.com.
Following the conference, the webcast will be archived on the AMAG
Pharmaceuticals, Inc. website until June 10, 2010.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes
its proprietary technology for the development and commercialization of
a therapeutic iron compound to treat iron deficiency anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease. On June 30, 2009, AMAG received approval from the U.S. Food and
Drug Administration to market Feraheme(R) (ferumoxytol)
Injection for intravenous (IV) use for the treatment of iron deficiency
anemia in adult chronic kidney disease patients. For additional company
and product information, please visit www.amagpharma.com.
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
SOURCE: AMAG Pharmaceuticals
AMAG Pharmaceuticals
Carol Miceli, 617-498-3361
